Complications in Hypertension and Obesity

This study is currently recruiting participants.
Verified January 2012 by Almazov Federal Center of Heart, Blood and Endocrinology
Sponsor:
Information provided by (Responsible Party):
Conrady Alexandra, Almazov Federal Center of Heart, Blood and Endocrinology
ClinicalTrials.gov Identifier:
NCT00552292
First received: October 31, 2007
Last updated: January 11, 2012
Last verified: January 2012

October 31, 2007
January 11, 2012
December 2007
Not Provided
cardiovascular complications [ Time Frame: 2007-2017 ] [ Designated as safety issue: No ]
cardiovascular complications [ Time Frame: 2007-2017 ]
Complete list of historical versions of study NCT00552292 on ClinicalTrials.gov Archive Site
diabetes mellitus [ Time Frame: 2007-2017 ] [ Designated as safety issue: No ]
diabetes mellitus [ Time Frame: 2007-2017 ]
Not Provided
Not Provided
 
Complications in Hypertension and Obesity
National Investigation of Cardiovascular Complications in Arterial Hypertension and Obesity

The study in aimed to investigate epidemiology of risk factors in Russian Federation its prognostic value aimed on acceptance of national specific definition of metabolic syndrome and guidelines for its management.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:

Blood, urine, serum

Non-Probability Sample

Age and sex-matched sample of subjects older 18 age

  • Metabolic Syndrome
  • Hypertension
  • Obesity
  • Dyslipidemia
  • Hyperglycemia
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
30000
January 2017
Not Provided

Inclusion Criteria:

  • Age older 18 years
  • Signed informed consent
  • Blood pressure more than 130 and/or 85 mm Hg
  • Waist circumference more than 80 sm in females and 94 in males and/or BMI more than 25 kg/m2
  • Dyslipidemia (elevated TG and/or decreased level of HDLP or therapy for high triglyceride level)
  • Fasting glucose more than 5,6 mmol/l

Exclusion Criteria:

  • Associated clinical conditions (stroke, TIA, MI, heart failure, renal disease, diabetes mellitus)
  • Severe concomitant diseases affecting outcome
Both
18 Years to 90 Years
No
Contact: Alexandra O Conrady, MD, PhD +7812-70255-71 ahleague@mail.ru
Contact: Elena I Baranova, professor 346-9082 ext +7812 eibaranova@yahoo.com
Russian Federation
 
NCT00552292
25/1
No
Conrady Alexandra, Almazov Federal Center of Heart, Blood and Endocrinology
Almazov Federal Center of Heart, Blood and Endocrinology
Not Provided
Study Director: Eugene V Shlyakhto Almazov Federal Center of Heart, Blood and Endocrinology
Almazov Federal Center of Heart, Blood and Endocrinology
January 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP